Contraceptive Market Overview, 2025-30

The global contraceptive market is witnessing significant growth driven by increasing awareness about reproductive health, expanding access to family planning services, and a rising demand for convenient, affordable, and effective contraceptive methods. A key factor fueling this growth is the introduction of over-the-counter (OTC) contraceptives such as Opill, the first FDA-approved daily oral contraceptive available without a prescription. Launched in early 2024, Opill offers a progestin-only option with approximately 91% effectiveness and is available at major retail chains, making contraceptive access easier for many, especially in regions with limited healthcare infrastructure.

The market itself is highly diversified, encompassing hormonal contraceptives like oral pills, implants, injectables, and intrauterine devices (IUDs), as well as barrier methods. There is a growing preference for long-acting reversible contraceptives (LARCs) due to their reliability and convenience, while male contraceptive options - such as topical gels and hormonal injectables - are progressing through research phases, potentially hitting the market before 2030. The level of mergers and acquisitions in the industry is moderate due to the stringent regulations and approvals required for contraceptive products to expand their industry presence.

However, companies leverage M&A to access new distribution channels, strengthen research and development capabilities, and consolidate market positions. For instance, in December 2022, Linden Capital Partners acquired LifeStyles Healthcare, a sexual health and wellness platform provider, from stakeholders, including Humanwell Healthcare and Trustar Capital. This acquisition is significant for Linden, a Chicago-based private equity firm specializing in the healthcare industry. Regulatory bodies such as the FDA in the U.S.

impose stringent requirements to ensure the safety, efficacy, and quality of products before they reach consumers. Changes in regulatory frameworks impact product development timelines, market entry strategies, and compliance costs for manufacturers. Moreover, government policies on reproductive health, including insurance coverage and family planning initiatives, shape demand dynamics and access to contraception globally.

According to the research report, "Global Contraceptive Market Overview, 2030," the Global Contraceptive market was valued at more than USD 31.20 Billion in 2024, with the CAGR of 6.61% from 2025-2030. Technological advancements have also played a crucial role in expanding the market. Innovations in contraceptive technology have led to the development of more effective, convenient, and safer methods, such as long-acting reversible contraceptives (LARCs), including intrauterine devices (IUDs) and implants, as well as hormone-based methods like patches and vaginal rings. These advancements have improved user compliance and satisfaction, thus increasing market penetration.

For example, newer hormonal contraceptives have minimized side effects and enhanced ease of use, encouraging more women to adopt these methods. Furthermore, the emergence of male contraceptive options, although still limited, signals future diversification in the market, potentially balancing contraceptive responsibility between genders. The level of mergers and acquisitions in the industry is moderate due to the stringent regulations and approvals required for contraceptive products to expand their industry presence. However, companies leverage M&A to access new distribution channels, strengthen research and development capabilities, and consolidate market positions.

For instance, in December 2022, Linden Capital Partners acquired LifeStyles Healthcare, a sexual health and wellness platform provider, from stakeholders, including Humanwell Healthcare and Trustar Capital. This acquisition is significant for Linden, a Chicago-based private equity firm specializing in the healthcare industry. In March 2024, Insud Pharma, a Spain-based pharmaceutical manufacturer, acquired oral and injectable contraceptives from Viatris for an undisclosed amount.

This acquisition allows Insud Pharma to strengthen its women's health product portfolio by incorporating Viatris' contraceptive offerings, expanding its market presence, and providing a wider range of reproductive healthcare solutions to meet the increasing demand for contraceptive options. Viatris, a US-based pharmaceutical company, specializes in the manufacturing of pharmaceuticals.

Market Drivers

• Increasing Global Focus on Women’s Health and Reproductive Rights:Worldwide, there is a growing emphasis on women’s health and reproductive autonomy, fueled by advocacy from international organizations, governments, and NGOs. The recognition that access to contraception is fundamental to gender equality and sustainable development has led to broader policy support and funding for family planning programs. Improved access to education and healthcare services for women, particularly in developing countries, is significantly increasing demand for various contraceptive methods. As women seek greater control over their reproductive choices, the global market continues to expand, especially for modern and long-acting contraceptives.
• Technological Innovations in Contraceptive Products:Ongoing research and development efforts are driving innovation in contraceptive technologies. Pharmaceutical and biotech companies are developing new methods that offer better efficacy, fewer side effects, and greater convenience. These include advancements in hormonal delivery systems, such as vaginal rings, patches, injectables, and male contraceptive solutions currently in development. Additionally, digital integration with fertility tracking apps and smart wearables is creating a new segment of tech-enabled contraception. These innovations are attracting a wider demographic and increasing user adherence, further driving global market growth.

Market Challenges

• Cultural, Religious, and Social Resistance:Despite global progress, cultural and religious opposition to contraception continues to be a significant barrier in many regions, particularly in parts of Africa, the Middle East, and South Asia. Deep-rooted beliefs often stigmatize the use of contraceptives, especially among unmarried women and adolescents. In some cases, political and religious leaders oppose government-sponsored family planning programs, making it difficult to implement widespread education and distribution efforts. This resistance not only slows market growth but also undermines public health goals related to population control and maternal well-being.
• Inequitable Access and Affordability Gaps: Access to contraception remains highly uneven across regions and socioeconomic groups. While high-income countries typically enjoy broad access through insurance or public health programs, millions in low- and middle-income countries face significant barriers due to cost, lack of infrastructure, or supply chain inefficiencies. Even when products are available, a shortage of trained healthcare providers and limited education on proper usage affect consistent uptake. Bridging these gaps requires substantial investment in healthcare systems, logistics, and culturally sensitive outreach efforts - challenges that persist despite global funding efforts.

Market Trends

• Rising Popularity of Long-Acting Reversible Contraceptives (LARCs):Globally, there is a clear trend toward long-acting reversible contraceptives such as intrauterine devices (IUDs) and hormonal implants. These methods offer high efficacy and convenience, requiring minimal maintenance and reducing the likelihood of user error. LARCs are particularly appealing to working women, adolescents, and those in regions with limited access to regular healthcare visits. As health systems and NGOs promote LARCs as a cost-effective, scalable solution, their adoption continues to rise in both developed and emerging markets.
• Expansion of Digital Health and E-Commerce Solutions:The integration of digital technology into reproductive healthcare is transforming how contraceptives are accessed and managed. Telemedicine platforms, mobile apps, and online pharmacies now offer virtual consultations, digital prescriptions, and home delivery services - making contraception more discreet and accessible, particularly in urban settings. Additionally, fertility-tracking apps are merging lifestyle data with contraceptive planning, empowering users to make informed choices. This digital trend is expected to reshape the consumer experience and significantly expand market reach, especially among tech-savvy younger populations.

The fastest growth in contraceptive devices is primarily driven by rising awareness of long-acting reversible contraceptives (LARCs), their high efficacy, and increasing preference for non-hormonal and low-maintenance birth control methods.

The global contraceptive industry is witnessing a notable surge in demand for contraceptive devices, primarily due to growing awareness and acceptance of long-acting reversible contraceptives (LARCs) such as intrauterine devices (IUDs) and subdermal implants. These methods offer significant advantages over traditional hormonal pills, including longer duration of effectiveness, minimal need for user intervention, and fewer systemic side effects, which are increasingly appreciated by both healthcare providers and users. As knowledge about reproductive health improves - driven by government campaigns, NGOs, and digital platforms - more individuals, especially women, are making informed choices toward safer and more convenient contraceptive options.

Contraceptive devices like IUDs, condoms, diaphragms, and implants also provide varying degrees of hormonal and non-hormonal solutions, giving users flexibility based on their health needs and preferences. Additionally, LARCs are highly cost-effective in the long run, making them appealing in both developed and emerging markets. Unlike pills, which require daily adherence and can result in user error or discontinuation, devices ensure high compliance, translating into greater efficacy in preventing unintended pregnancies. This factor is crucial in regions grappling with high fertility rates and limited healthcare access, as devices require fewer follow-ups and reduce the burden on healthcare infrastructure.

Moreover, innovations in device design - such as hormone-releasing IUDs with lower doses and minimal side effects, or biodegradable implants - are further enhancing user confidence and expanding their appeal. The rising female workforce participation and urbanization are also contributing to this shift, as modern lifestyles demand reliable and hassle-free contraceptive solutions. Additionally, increasing support from international health organizations, which promote device-based contraceptives in family planning initiatives, has significantly boosted adoption, especially in countries with strong population control policies.

The fastest growth in contraceptive use among the 44+ age group globally is primarily driven by increased health awareness, extended reproductive years due to later-life pregnancies, and a rising emphasis on personal autonomy and family planning in older women.

The contraceptive industry is witnessing a notable surge in demand among women aged 44 and above, and this shift is fundamentally anchored in a blend of medical, societal, and demographic changes reshaping modern reproductive behavior. A primary driver is the rising health awareness among older women who increasingly recognize the risks of unplanned pregnancies at a later age, both for themselves and potential offspring. As advancements in healthcare and fertility technologies extend reproductive potential into the late 40s and early 50s, women are remaining sexually active longer and, correspondingly, require reliable contraceptive options to manage their reproductive choices effectively.

Moreover, global trends such as delayed marriage, late childbearing, and second marriages have altered traditional reproductive timelines, compelling women in this age group to actively engage in family planning. The stigma once associated with contraception in older women is fading, replaced by a broader cultural shift toward personal empowerment, bodily autonomy, and holistic health management. Additionally, menopause transition is no longer viewed as an abrupt end to reproductive concern but a stage requiring continued contraceptive vigilance due to irregular ovulation and the persistent possibility of pregnancy.

Hormonal contraceptives, in particular, are also being prescribed not solely for birth control but for managing perimenopausal symptoms like hot flashes, irregular cycles, and hormonal imbalances, thereby expanding their utility in this demographic. On the supply side, pharmaceutical companies are increasingly tailoring contraceptive products to address the unique physiological and hormonal needs of older women, offering lower-dose, safer, and multi-benefit formulations. Coupled with easier access to telemedicine and digital health platforms, older women are now more empowered to seek personalized contraceptive solutions discreetly and conveniently.

The male gender type is the fastest growing segment in the global contraceptive industry due to increasing demand for shared responsibility in family planning, advancements in male contraceptive technologies, and rising awareness of men’s reproductive health.

The global contraceptive industry has witnessed a significant surge in demand for male contraceptive options, marking the male gender segment as the fastest growing in this sector. This trend can be largely attributed to a shifting societal paradigm where men are increasingly encouraged to take an active role in family planning rather than leaving the responsibility solely to women. Traditional contraceptive methods have predominantly focused on women, such as oral pills, intrauterine devices (IUDs), and hormonal implants, often placing the burden of birth control largely on female partners.

However, as gender equality movements gain momentum globally, there is a growing recognition that contraceptive responsibility should be shared equally between partners. This cultural shift has stimulated interest and acceptance of male-oriented contraceptive solutions. Furthermore, scientific advancements have played a crucial role in accelerating the growth of male contraceptive options. Researchers and pharmaceutical companies are now investing significantly in the development of novel male contraceptives, including hormonal pills, gels, and non-hormonal methods that are safer, reversible, and more effective.

These innovations are addressing historical concerns related to side effects, efficacy, and convenience that previously limited male participation in contraception. For example, recent breakthroughs in male hormonal contraceptives have shown promising results in clinical trials, indicating a potential shift from temporary methods like condoms and vasectomies to more user-friendly, long-acting options. Additionally, increased awareness and education about men’s reproductive health have fueled demand for male contraceptives.

Public health campaigns and advocacy groups emphasize the importance of men understanding their reproductive choices and the impact of contraception on overall family wellbeing. The availability of information through digital platforms has empowered men to make informed decisions, contributing to greater acceptance and utilization of male contraceptives.

Hospitals and gynecology clinics are the fastest-growing end-user segment in the global contraceptive industry due to increasing awareness, improved healthcare infrastructure, and a rising preference for professional medical guidance in contraceptive use.

The rapid growth of hospitals and gynecology clinics as key end users in the global contraceptive market can be attributed to multiple interconnected factors. Primarily, there is a growing awareness among women and couples worldwide about reproductive health, family planning, and the benefits of modern contraceptive methods. This heightened awareness has been driven by extensive government initiatives, NGO campaigns, and educational programs aimed at promoting safe and effective contraceptive use. Consequently, more individuals are seeking professional advice to choose suitable contraceptive options, making hospitals and specialized gynecology clinics the preferred venues for consultation and procurement.

Additionally, significant improvements in healthcare infrastructure, especially in emerging economies, have expanded access to quality medical facilities. With better-equipped hospitals and specialized clinics, healthcare providers can offer a wide range of contraceptive products, including long-acting reversible contraceptives (LARCs) like intrauterine devices (IUDs) and implants, as well as hormonal contraceptives and emergency contraception. These facilities also enable thorough patient education, counseling, and follow-up, which are critical for adherence and effective contraceptive use.

Moreover, there is a rising trend among women and couples to seek personalized contraceptive solutions under medical supervision rather than relying on over-the-counter or informal channels. This preference stems from a desire to ensure safety, manage side effects, and tailor choices to individual health conditions and lifestyle needs. Gynecology clinics, staffed by specialists in women’s reproductive health, provide the expertise necessary to guide users through this decision-making process, reinforcing trust and driving demand.

Online channels are the fastest-growing distribution type in the global contraceptive industry due to their unparalleled convenience, privacy, and accessibility, which align perfectly with consumer preferences in an increasingly digital and health-conscious world.

The rapid expansion of online channels as a distribution method in the global contraceptive industry is driven primarily by the evolving consumer behaviors and technological advancements that prioritize ease, discretion, and direct access to products. Unlike traditional retail or pharmacy channels, online platforms offer users the ability to purchase contraceptives discreetly without the stigma or embarrassment sometimes associated with in-person buying. This privacy factor is crucial, especially in regions where cultural taboos or social norms limit open discussion about sexual health. Additionally, the convenience of ordering anytime and anywhere removes significant barriers related to physical store hours and location constraints.

Consumers increasingly prefer to manage their health and wellness needs digitally, a trend accelerated by smartphone proliferation and improved internet connectivity worldwide. Moreover, online distribution channels often provide a broader selection of contraceptive products, including newer or niche options that may not be readily available in local stores, allowing consumers to make more informed choices tailored to their specific needs. Many online platforms also enhance the buying experience through detailed product descriptions, user reviews, and expert consultations, which empower customers to make confident decisions without needing to consult healthcare providers physically.

Subscription models and doorstep delivery services further simplify ongoing contraceptive use, promoting adherence and consistent usage, which are vital for effectiveness. The COVID-19 pandemic amplified the shift to online shopping by restricting access to physical outlets and increasing public health concerns around in-person interactions, reinforcing digital channels as essential for healthcare product distribution. Additionally, digital marketing strategies enable companies to target specific demographics more precisely and educate consumers about sexual health, thereby expanding market reach.

The Middle East and Africa are experiencing growth in the global contraceptive industry primarily due to increasing awareness and government initiatives promoting family planning and reproductive health services.

The growth of the contraceptive industry in the Middle East and Africa can be largely attributed to a combination of rising public awareness and expanding government support for family planning programs. Over the past decade, many countries in these regions have recognized the critical role that reproductive health plays in socio-economic development. As a result, governments and international organizations have begun implementing targeted campaigns to educate populations about the benefits of contraceptives, such as reducing unintended pregnancies, lowering maternal mortality rates, and empowering women to make informed choices about their reproductive lives.

These educational initiatives, often led by public health institutions and supported by NGOs, are gradually dismantling the cultural and religious stigmas traditionally associated with contraceptive use in more conservative societies. Furthermore, population growth pressures have pushed policymakers to act. With some of the highest fertility rates in the world, particularly in Sub-Saharan Africa, countries are increasingly seeing the need to manage demographic expansion to ensure sustainable development, resource management, and economic stability. Simultaneously, improvements in healthcare infrastructure, along with increased investments by private and international players in the pharmaceutical and healthcare sectors, have enhanced the availability and affordability of contraceptive products. Mobile health technologies and community-based distribution systems have also played a crucial role in bridging the gap between urban centers and remote areas, enabling wider access to contraceptives.

• In March 2024, Perrigo Company plc announced the availability of its oral contraceptive pill, Opill, without a prescription in the U.S. It is also available for sale online on the company's website.
• In October 2023, Xiromed launched a generic version of Nuvaring, a vaginal ring, EnilloRing. The launch of this product offers an additional contraceptive option to patients in the U.S.
• In March 2023, NEXT Life Sciences, Inc., a medical device company, launched a new contraceptive product for men to market, Plan A. The development of this product is to offer fully reversible birth control, safe and effective for men.
• In April 2023, Veru Inc. entered into an agreement with Afaxys Group Services, LLC (AGS) to distribute FC2 Female Condom of Veru with the support of AGS's Group Purchasing Organization (GPO). This partnership aims to support over 31 million individuals who depend on public health and community centers for essential healthcare services, benefiting both men and women.

Considered in this report

• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report

• Contraceptive Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product

• Contraceptive Drugs
• Contraceptive Devices

By Age Group

• 15 - 44 years
• Above 44 years

By Gender

• Female
• Male

By Distribution Channels

• Retail pharmacies
• Hospital pharmacies
• Online channels
• Other distribution channels

The approach of the report:

This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analyzing the government generated reports and databases.

After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.

Intended audience

This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to this industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.